{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:36:02Z","timestamp":1770723362456,"version":"3.49.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T00:00:00Z","timestamp":1349740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T00:00:00Z","timestamp":1349740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1038\/tpj.2012.41","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T10:04:02Z","timestamp":1349777042000},"page":"453-461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies"],"prefix":"10.1038","volume":"12","author":[{"given":"V","family":"Foti Cuzzola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Palella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Celi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Barresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Giacoppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,9]]},"reference":[{"key":"BFtpj201241_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1878-5085-3-9","volume":"3","author":"N Borisow","year":"2012","unstructured":"Borisow N, Doring A, Pfueller CF, Paul F, Dorr J, Hellwig K . Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J 2012; 3: 9.","journal-title":"EPMA J"},{"key":"BFtpj201241_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/bmb\/ldq017","volume":"95","author":"K Rejdak","year":"2010","unstructured":"Rejdak K, Jackson S, Giovannoni G . Multiple sclerosis: a practical overview for clinicians. Br Med Bull 2010; 95: 79\u2013104.","journal-title":"Br Med Bull"},{"key":"BFtpj201241_CR3","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1001\/archinte.162.19.2161","volume":"162","author":"SL Galetta","year":"2002","unstructured":"Galetta SL, Markowitz C, Lee AG . Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002; 162: 2161\u20132169.","journal-title":"Arch Intern Med"},{"key":"BFtpj201241_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292\u2013302.","journal-title":"Ann Neurol"},{"key":"BFtpj201241_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1191\/1352458503ms948oa","volume":"9","author":"M Trojano","year":"2003","unstructured":"Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 2003; 9: 451\u2013457.","journal-title":"Mult Scler"},{"key":"BFtpj201241_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/1756285612450936","volume":"5","author":"W Castro-Borrero","year":"2012","unstructured":"Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2012; 5: 205\u2013220.","journal-title":"Ther Adv Neurol Disord"},{"key":"BFtpj201241_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/187153007780059414","volume":"7","author":"C Kleinschnitz","year":"2007","unstructured":"Kleinschnitz C, Meuth SG, Kieseier BC, Wiendl H . Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets 2007; 7: 35\u201363.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"BFtpj201241_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1089\/jir.2010.0089","volume":"30","author":"RA Farrell","year":"2010","unstructured":"Farrell RA, Giovannoni G . Current and future role of interferon beta in the therapy of multiple sclerosis. J Interferon Cytokine Res 2010; 30: 715\u2013726.","journal-title":"J Interferon Cytokine Res"},{"key":"BFtpj201241_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"BD Trapp","year":"1998","unstructured":"Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L . Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278\u2013285.","journal-title":"N Engl J Med"},{"key":"BFtpj201241_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1212\/WNL.60.1.44","volume":"60","author":"SM Leary","year":"2003","unstructured":"Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ . Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44\u201351.","journal-title":"Neurology"},{"key":"BFtpj201241_CR11","doi-asserted-by":"crossref","unstructured":"Montalban X . Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler. 2004; 10 (Suppl 1): S62 discussion 62\u20134.","DOI":"10.1191\/1352458504ms1033oa"},{"issue":"Suppl 1","key":"BFtpj201241_CR12","first-page":"S65","volume":"10","author":"JS Wolinsky","year":"2004","unstructured":"Wolinsky JS . PROMiSe Trial Study Group. The PROMiSe trial: baseline data review and progress report. Mult Scler 2004; 10 (Suppl 1): S65\u2013S71, discussion S71\u20132.","journal-title":"Mult Scler"},{"key":"BFtpj201241_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1212\/WNL.46.2.552","volume":"46","author":"LK Neilley","year":"1996","unstructured":"Neilley LK, Goodin DS, Goodkin DE, Hauser SL . Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996; 46: 552\u2013554.","journal-title":"Neurology"},{"key":"BFtpj201241_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nrd2422","volume":"6","author":"EC Borden","year":"2007","unstructured":"Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6: 975\u2013990.","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 2","key":"BFtpj201241_CR15","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1007\/s10072-009-0146-3","volume":"30","author":"C Gasperini","year":"2009","unstructured":"Gasperini C, Ruggieri S . New oral drugs for multiple sclerosis. Neurol Sci 2009; 30 (Suppl 2): S179\u2013S183.","journal-title":"Neurol Sci"},{"key":"BFtpj201241_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.nurt.2007.08.003","volume":"4","author":"O Neuhaus","year":"2007","unstructured":"Neuhaus O, Kieseier BC, Hartung HP . Immunosuppressive agents in multiple sclerosis. Neurotherapeutics 2007; 4: 654\u2013660.","journal-title":"Neurotherapeutics"},{"key":"BFtpj201241_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","volume":"348","author":"DH Miller","year":"2003","unstructured":"Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15\u201323.","journal-title":"N Engl J Med"},{"key":"BFtpj201241_CR18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1212\/WNL.59.6.954","volume":"59","author":"D Brassat","year":"2002","unstructured":"Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002; 59: 954\u2013955.","journal-title":"Neurology"},{"key":"BFtpj201241_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S1474-4422(10)70088-0","volume":"9","author":"HP Hartung","year":"2010","unstructured":"Hartung HP, Aktas O . Oral therapies for multiple sclerosis: are we there yet? Lancet Neurol 2010; 9: 454\u2013457.","journal-title":"Lancet Neurol"},{"key":"BFtpj201241_CR20","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/j.1476-5381.2009.00451.x","volume":"158","author":"V Brinkmann","year":"2009","unstructured":"Brinkmann V . FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009; 158: 1173\u20131182.","journal-title":"Br J Pharmacol"},{"key":"BFtpj201241_CR21","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.4049\/jimmunol.171.5.2694","volume":"171","author":"B Weinstock-Guttman","year":"2003","unstructured":"Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003; 171: 2694\u20132702.","journal-title":"J Immunol"},{"key":"BFtpj201241_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0952-7915(01)00305-3","volume":"14","author":"T Taniguchi","year":"2002","unstructured":"Taniguchi T, Takaoka A . The interferon-alpha\/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002; 14: 111\u2013116.","journal-title":"Curr Opin Immunol"},{"key":"BFtpj201241_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jneuroim.2008.09.004","volume":"205","author":"B Weinstock-Guttman","year":"2008","unstructured":"Weinstock-Guttman B, Bhasi K, Badgett D, Tamano-Blanco M, Minhas M, Feichter J et al. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 2008; 205: 113\u2013125.","journal-title":"J Neuroimmunol"},{"issue":"Pt 6","key":"BFtpj201241_CR24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/brain\/awg147","volume":"126","author":"S Sturzebecher","year":"2003","unstructured":"Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126 (Pt 6): 1419\u20131429.","journal-title":"Brain"},{"key":"BFtpj201241_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jneuroim.2007.11.007","volume":"194","author":"RL Lindberg","year":"2008","unstructured":"Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L . Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008; 194: 153\u2013164.","journal-title":"J Neuroimmunol"},{"key":"BFtpj201241_CR26","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/archneurol.2009.150","volume":"66","author":"M Comabella","year":"2009","unstructured":"Comabella M, Craig DW, Morcillo-Suarez C, Rio J, Navarro A, Fernandez M et al. Genome-wide scan of 500\u2009000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009; 66: 972\u2013978.","journal-title":"Arch Neurol"},{"key":"BFtpj201241_CR27","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1074\/jbc.274.7.4370","volume":"274","author":"G Kochs","year":"1999","unstructured":"Kochs G, Haller OGTP . bound human MxA protein interacts with the nucleocapsids of Thogoto virus (Orthomyxoviridae). J Biol Chem 1999; 274: 4370\u20134376.","journal-title":"J Biol Chem"},{"key":"BFtpj201241_CR28","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00705-008-0168-9","volume":"153","author":"Z Yu","year":"2008","unstructured":"Yu Z, Wang Z, Chen J, Li H, Lin Z, Zhang F et al. GTPase activity is not essential for the interferon-inducible MxA protein to inhibit the replication of hepatitis B virus. Arch Virol 2008; 153: 1677\u20131684.","journal-title":"Arch Virol"},{"key":"BFtpj201241_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.1365-2990.2003.00468.x","volume":"29","author":"JB Lampe","year":"2003","unstructured":"Lampe JB, Schneider-Schaulies S, Aguzzi A . Expression of the interferon-induced MxA protein in viral encephalitis. Neuropathol Appl Neurobiol 2003; 29: 273\u2013279.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"BFtpj201241_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1468-1331.2009.02573.x","volume":"16","author":"AN Al-Masri","year":"2009","unstructured":"Al-Masri AN, Heidenreich F, Walter GF . Interferon-induced Mx proteins in brain tissue of multiple sclerosis patients. Eur J Neurol 2009; 16: 721\u2013726.","journal-title":"Eur J Neurol"},{"key":"BFtpj201241_CR31","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1089\/jir.1998.18.1025","volume":"18","author":"E Pungor","year":"1998","unstructured":"Pungor E, Files JG, Gabe JD, Do LT, Foley WP, Gray JL et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 1998; 18: 1025\u20131030.","journal-title":"J Interferon Cytokine Res"},{"key":"BFtpj201241_CR32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1212\/WNL.54.1.193","volume":"54","author":"A Kracke","year":"2000","unstructured":"Kracke A, von Wussow P, Al-Masri AN, Dalley G, Windhagen A, Heidenreich F . Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 2000; 54: 193\u2013199.","journal-title":"Neurology"},{"key":"BFtpj201241_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3109\/08916930903219040","volume":"43","author":"P Serrano-Fernandez","year":"2010","unstructured":"Serrano-Fernandez P, Moller S, Goertsches R, Fiedler H, Koczan D, Thiesen HJ et al. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity 2010; 43: 172\u2013178.","journal-title":"Autoimmunity"},{"key":"BFtpj201241_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jneuroim.2008.04.036","volume":"199","author":"J Hilpert","year":"2008","unstructured":"Hilpert J, Beekman JM, Schwenke S, Kowal K, Bauer D, Lampe J et al. Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. J Neuroimmunol 2008; 199: 115\u2013125.","journal-title":"J Neuroimmunol"},{"key":"BFtpj201241_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.gene.6363946","volume":"4","author":"U Sriram","year":"2003","unstructured":"Sriram U, Barcellos LF, Villoslada P, Rio J, Baranzini SE, Caillier S et al. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 2003; 4: 147\u2013152.","journal-title":"Genes Immun"},{"key":"BFtpj201241_CR36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.clpt.2005.08.018","volume":"78","author":"S Cunningham","year":"2005","unstructured":"Cunningham S, Graham C, Hutchinson M, Droogan A, O'Rourke K, Patterson C et al. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther 2005; 78: 635\u2013646.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201241_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jneuroim.2005.02.010","volume":"163","author":"L Leyva","year":"2005","unstructured":"Leyva L, Fernandez O, Fedetz M, Blanco E, Fernandez VE, Oliver B et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 2005; 163: 165\u2013171.","journal-title":"J Neuroimmunol"},{"key":"BFtpj201241_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jneuroim.2006.11.010","volume":"183","author":"B Oliver","year":"2007","unstructured":"Oliver B, Mayorga C, Fernandez V, Leyva L, Leon A, Luque G et al. Interferon receptor expression in multiple sclerosis patients. J Neuroimmunol 2007; 183: 225\u2013231.","journal-title":"J Neuroimmunol"},{"key":"BFtpj201241_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jneuroim.2008.03.019","volume":"197","author":"F Serana","year":"2008","unstructured":"Serana F, Sottini A, Ghidini C, Zanotti C, Capra R, Cordioli C et al. Modulation of IFNAR1 mRNA expression in multiple sclerosis patients. J Neuroimmunol 2008; 197: 54\u201362.","journal-title":"J Neuroimmunol"},{"key":"BFtpj201241_CR40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/archneurol.2008.47","volume":"65","author":"E Byun","year":"2008","unstructured":"Byun E, Caillier SJ, Montalban X, Villoslada P, Fernandez O, Brassat D et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337\u2013344.","journal-title":"Arch Neurol"},{"key":"BFtpj201241_CR41","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/gb-2008-9-5-224","volume":"9","author":"J Filmus","year":"2008","unstructured":"Filmus J, Capurro M, Rast J . Glypicans. Genome Biol 2008; 9: 224.","journal-title":"Genome Biol"},{"key":"BFtpj201241_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.conb.2006.01.011","volume":"16","author":"D Van Vactor","year":"2006","unstructured":"Van Vactor D, Wall DP, Johnson KG . Heparan sulfate proteoglycans and the emergence of neuronal connectivity. Curr Opin Neurobiol 2006; 16: 40\u201351.","journal-title":"Curr Opin Neurobiol"},{"key":"BFtpj201241_CR43","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1177\/1352458509106509","volume":"15","author":"MD Cenit","year":"2009","unstructured":"Cenit MD, Blanco-Kelly F, de las Heras V, Bartolome M, de la Concha EG, Urcelay E et al. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler 2009; 15: 913\u2013917.","journal-title":"Mult Scler"},{"key":"BFtpj201241_CR44","doi-asserted-by":"publisher","first-page":"14199","DOI":"10.1073\/pnas.1002494107","volume":"107","author":"T Tsunoda","year":"2010","unstructured":"Tsunoda T, Takashima Y, Tanaka Y, Fujimoto T, Doi K, Hirose Y et al. Immune-related zinc finger gene ZFAT is an essential transcriptional regulator for hematopoietic differentiation in blood islands. Proc Natl Acad Sci USA 2010; 107: 14199\u201314204.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201241_CR45","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1248\/bpb.29.1830","volume":"29","author":"K Hemmi","year":"2006","unstructured":"Hemmi K, Ma D, Miura Y, Kawaguchi M, Sasahara M, Hashimoto-Tamaoki T et al. A homeodomain-zinc finger protein, ZFHX4, is expressed in neuronal differentiation manner and suppressed in muscle differentiation manner. Biol Pharm Bull 2006; 29: 1830\u20131835.","journal-title":"Biol Pharm Bull"},{"key":"BFtpj201241_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1468-1331.2004.01102.x","volume":"12","author":"S Wergeland","year":"2005","unstructured":"Wergeland S, Beiske A, Nyland H, Hovdal H, Jensen D, Larsen JP et al. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol 2005; 12: 171\u2013175.","journal-title":"Eur J Neurol"},{"key":"BFtpj201241_CR47","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/hep.510300207","volume":"30","author":"CJ Edwards-Smith","year":"1999","unstructured":"Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE . Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30: 526\u2013530.","journal-title":"Hepatology"},{"key":"BFtpj201241_CR48","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2217\/pgs.09.152","volume":"11","author":"RH Goertsches","year":"2010","unstructured":"Goertsches RH, Hecker M, Koczan D, Serrano-Fernandez P, Moeller S, Thiesen HJ et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010; 11: 147\u2013161.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201241_CR49","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1096\/fj.05-5493fje","volume":"20","author":"H Qin","year":"2006","unstructured":"Qin H, Wilson CA, Lee SJ, Benveniste EN . IFN-beta-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia. FASEB J 2006; 20: 985\u2013987.","journal-title":"FASEB J"},{"key":"BFtpj201241_CR50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.nrl.2010.06.003","volume":"26","author":"AL Guerrero","year":"2011","unstructured":"Guerrero AL, Tejero MA, Gutierrez F, Martin-Polo J, Iglesias F, Laherran E et al. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis. Neurologia 2011; 26: 137\u2013142.","journal-title":"Neurologia"},{"key":"BFtpj201241_CR51","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000323982","volume":"65","author":"O Carmona","year":"2011","unstructured":"Carmona O, Masuet C, Alia P, Moral E, Alonso-Magdalena L, Casado V et al. Apolipoprotein alleles and the response to interferon-beta-1b in multiple sclerosis. Eur Neurol 2011; 65: 132\u2013137.","journal-title":"Eur Neurol"},{"key":"BFtpj201241_CR52","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1089\/107999002753536149","volume":"22","author":"AJ da Silva","year":"2002","unstructured":"da Silva AJ, Brickelmaier M, Majeau GR, Lukashin AV, Peyman J, Whitty A et al. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J Interferon Cytokine Res 2002; 22: 173\u2013188.","journal-title":"J Interferon Cytokine Res"},{"key":"BFtpj201241_CR53","doi-asserted-by":"publisher","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","volume":"95","author":"SD Der","year":"1998","unstructured":"Der SD, Zhou A, Williams BR, Silverman RH . Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95: 15623\u201315628.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtpj201241_CR54","first-page":"369","volume":"3","author":"D Paolicelli","year":"2009","unstructured":"Paolicelli D, Direnzo V, Trojano M . Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics 2009; 3: 369\u2013376.","journal-title":"Biologics"},{"key":"BFtpj201241_CR55","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/ana.20740","volume":"59","author":"J Rio","year":"2006","unstructured":"Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344\u2013352.","journal-title":"Ann Neurol"},{"key":"BFtpj201241_CR56","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1212\/01.WNL.0000078888.07196.0B","volume":"61","author":"E Waubant","year":"2003","unstructured":"Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184\u2013189.","journal-title":"Neurology"},{"key":"BFtpj201241_CR57","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1177\/1352458510373264","volume":"16","author":"C Enevold","year":"2010","unstructured":"Enevold C, Oturai AB, Sorensen PS, Ryder LP, Koch-Henriksen N, Bendtzen K . Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. Mult Scler 2010; 16: 942\u2013949.","journal-title":"Mult Scler"},{"key":"BFtpj201241_CR58","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.clim.2008.04.007","volume":"128","author":"E Wiesemann","year":"2008","unstructured":"Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A . Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin Immunol 2008; 128: 306\u2013313.","journal-title":"Clin Immunol"},{"key":"BFtpj201241_CR59","doi-asserted-by":"publisher","first-page":"e1927","DOI":"10.1371\/journal.pone.0001927","volume":"3","author":"LG van Baarsen","year":"2008","unstructured":"van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 2008; 3: e1927.","journal-title":"PLoS One"},{"key":"BFtpj201241_CR60","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ana.20224","volume":"56","author":"RA Rudick","year":"2004","unstructured":"Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E . Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548\u2013555.","journal-title":"Ann Neurol"},{"key":"BFtpj201241_CR61","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1191\/1352458504ms1021sr","volume":"10","author":"A Petzold","year":"2004","unstructured":"Petzold A, Brassat D, Mas P, Rejdak K, Keir G, Giovannoni G et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 2004; 10: 281\u2013283.","journal-title":"Mult Scler"},{"key":"BFtpj201241_CR62","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.49.3.862","volume":"49","author":"LA Stone","year":"1997","unstructured":"Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997; 49: 862\u2013869.","journal-title":"Neurology"},{"issue":"Suppl","key":"BFtpj201241_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2005.09.008","volume":"25","author":"F Macciardi","year":"2005","unstructured":"Macciardi F, Boneschi FM, Cohen D . Pharmacogenetics of autoimmune diseases: research issues in the case of multiple sclerosis and the role of IFN-beta. J Autoimmun 2005; 25 (Suppl): 1\u20135.","journal-title":"J Autoimmun"},{"key":"BFtpj201241_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0165-5728(98)00191-X","volume":"92","author":"A Miller","year":"1998","unstructured":"Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2\/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113\u2013121.","journal-title":"J Neuroimmunol"},{"key":"BFtpj201241_CR65","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.4049\/jimmunol.172.11.7144","volume":"172","author":"HJ Kim","year":"2004","unstructured":"Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172: 7144\u20137153.","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"BFtpj201241_CR66","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00415-008-1005-5","volume":"255","author":"F Blanchette","year":"2008","unstructured":"Blanchette F, Neuhaus O . Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 2008; 255 (Suppl 1): 26\u201336.","journal-title":"J Neurol"},{"key":"BFtpj201241_CR67","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/WNL.57.11.1976","volume":"57","author":"C Fusco","year":"2001","unstructured":"Fusco C, Andreone V, Coppola G, Luongo V, Guerini F, Pace E et al. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology 2001; 57: 1976\u20131979.","journal-title":"Neurology"},{"key":"BFtpj201241_CR68","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1385\/MN:27:2:163","volume":"27","author":"H Nakanishi","year":"2003","unstructured":"Nakanishi H . Microglial functions and proteases. Mol Neurobiol 2003; 27: 163\u2013176.","journal-title":"Mol Neurobiol"},{"key":"BFtpj201241_CR69","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1002\/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO;2-O","volume":"31","author":"H Beck","year":"2001","unstructured":"Beck H, Schwarz G, Schroter CJ, Deeg M, Baier D, Stevanovic S et al. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol 2001; 31: 3726\u20133736.","journal-title":"Eur J Immunol"},{"key":"BFtpj201241_CR70","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/FPC.0b013e3281299169","volume":"17","author":"I Grossman","year":"2007","unstructured":"Grossman I, Avidan N, Singer C, Goldstaub D, Hayardeny L, Eyal E et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics 2007; 17: 657\u2013666.","journal-title":"Pharmacogenet Genomics"},{"issue":"Suppl 1","key":"BFtpj201241_CR71","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1212\/WNL.0b013e3181c980fb","volume":"74","author":"DJ Pappas","year":"2010","unstructured":"Pappas DJ, Oksenberg JR . Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy. Neurology 2010; 74 (Suppl 1): S62\u2013S69.","journal-title":"Neurology"},{"key":"BFtpj201241_CR72","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/1352458506074510","volume":"13","author":"RM Valenzuela","year":"2007","unstructured":"Valenzuela RM, Costello K, Chen M, Said A, Johnson KP, Dhib-Jalbut S . Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler 2007; 13: 754\u2013762.","journal-title":"Mult Scler"},{"key":"BFtpj201241_CR73","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2217\/pgs.11.136","volume":"13","author":"EY Tsareva","year":"2012","unstructured":"Tsareva EY, Kulakova OG, Boyko AN, Shchur SG, Lvovs D, Favorov AV et al. Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. Pharmacogenomics 2012; 13: 43\u201353.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201241_CR74","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s00018-003-3336-9","volume":"61","author":"PM Jones","year":"2004","unstructured":"Jones PM, George AM . The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 2004; 61: 682\u2013699.","journal-title":"Cell Mol Life Sci"},{"key":"BFtpj201241_CR75","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","volume":"2","author":"W Loscher","year":"2005","unstructured":"Loscher W, Potschka H . Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2: 86\u201398.","journal-title":"NeuroRx"},{"issue":"Pt 9","key":"BFtpj201241_CR76","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/brain\/awp164","volume":"132","author":"S Cotte","year":"2009","unstructured":"Cotte S, von Ahsen N, Kruse N, Huber B, Winkelmann A, Zettl UK et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 2009; 132 (Pt 9): 2517\u20132530.","journal-title":"Brain"},{"key":"BFtpj201241_CR77","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jneuroim.2010.07.012","volume":"227","author":"A Millonig","year":"2010","unstructured":"Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M et al. Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol 2010; 227: 190\u2013194.","journal-title":"J Neuroimmunol"},{"key":"BFtpj201241_CR78","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/1352458509355068","volume":"16","author":"J Mellergard","year":"2010","unstructured":"Mellergard J, Edstrom M, Vrethem M, Ernerudh J, Dahle C . Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 2010; 16: 208\u2013217.","journal-title":"Mult Scler"},{"key":"BFtpj201241_CR79","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1468-1331.2009.02532.x","volume":"16","author":"M Khademi","year":"2009","unstructured":"Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009; 16: 528\u2013536.","journal-title":"Eur J Neurol"},{"key":"BFtpj201241_CR80","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1212\/WNL.0b013e3181ebdd64","volume":"75","author":"M Mehling","year":"2010","unstructured":"Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010; 75: 403\u2013410.","journal-title":"Neurology"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201241","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:26:58Z","timestamp":1647944818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,9]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["BFtpj201241"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2012.41","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,9]]},"assertion":[{"value":"11 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}